Corcept Therapeutics vs Xeris Biopharma
CORT and XERS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CORT and XERS compare
Corcept Therapeutics is the larger company, worth 4.5 times as much as Xeris Biopharma ($8.8B against $2.0B).
Xeris Biopharma grew revenue faster over the last twelve months (36.3% versus 16.0% for Corcept Therapeutics).
Corcept Therapeutics keeps more of each dollar of sales as profit, with a net margin of 6.6% compared with −5.1% at Xeris Biopharma.
Corcept Therapeutics scores higher on the StockData Score (11 against 9 for Xeris Biopharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CORT | XERS |
|---|---|---|
| Size and price | ||
| Market cap | $8.8B | $2.0B |
| Share price | $81.12 | $10.71 |
| Change, 1 year | 12.6% | 11.3% |
| Change, 5 years | 292% | 449% |
| Beta (5Y) | 0.55 | 1.24 |
| Employees | 730 | 435 |
| StockData Score | ||
| Total score | 11 (better) | 9 |
| Valuation score | 0 | 0 |
| Growth score | 3 | 4 (better) |
| Performance score | 2 | 3 (better) |
| Health score | 6 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 193× | – |
| P/S | 10.6× | 5.8× (better) |
| P/B | 12.4× | – |
| EV/EBITDA | 1047× | 54.9× (better) |
| P/FCF | 82.0× | – |
| FCF yield | 1.2% | – |
| Fair value | $15.98 | – |
| Margin of safety | −408% | – |
| Growth | ||
| Revenue growth (TTM) | 16.0% | 36.3% (better) |
| Revenue growth, 5Y average | 16.6% | 70.2% (better) |
| Net income growth (TTM) | −58.7% | – |
| EPS growth (TTM) | −62.5% | – |
| EPS growth, 5Y average | −0.72% | – |
| Profitability | ||
| Gross margin | 98.3% (better) | 86.6% |
| Operating margin | 0.77% | 10.9% (better) |
| Net margin | 6.6% (better) | −5.1% |
| FCF margin | 12.9% | – |
| Return on equity | 8.2% | – |
| Return on invested capital | 1.9% | 22.1% (better) |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Net debt / EBITDA | – | 3.45 |
| Interest coverage | – | 1.3× |
| Current ratio | 2.86 (better) | 1.45 |
| Altman Z-score | 31.14 (better) | 1.75 |
| Piotroski F-score | 4 | 8 (better) |
| Dividends and buybacks | ||
| Buyback yield | 0.48% | – |
| Shareholder yield | 0.48% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 76.2% | 59.4% |
| Held by insiders | 14.4% | 5.2% |
| Insider net buying, 12 months | −$92.1M | −$5.0M (better) |
| Short interest, % of float | 9.2% | 4.2% |
Go deeper
- CORT stock overview
- CORT income statement
- CORT valuation and score
- XERS stock overview
- XERS income statement
- XERS valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.